{
    "id": 22497,
    "fullName": "ABL1 F359C",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 F359C lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359C has been identified as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 19798095, PMID: 26773037), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 5510,
                    "pubMedId": 19798095,
                    "title": "Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19798095"
                },
                {
                    "id": 11530,
                    "pubMedId": 26773037,
                    "title": "The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26773037"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "F359C",
    "createDate": "05/12/2016",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119170,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130873028T>G",
        "cDna": "c.1076T>G",
        "protein": "p.F359C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20137,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F359C (NCCN.org).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6257,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 14% (1/7) of chronic myeloid leukemia patients harboring ABL1 F359C in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18916,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F359C (NCCN.org).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 F359C demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 23152,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359C"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7979,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of F359C/T315I (76%), F359C (12%), and F359C/V299L (9%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26123,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 T315I ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7981,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in a clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359C/F317L (73%), F359C/T315I (21%), and F359C (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26125,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23079,
            "profileName": "ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23080,
            "profileName": "BCR - ABL1 ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23149,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23150,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23152,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26123,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 T315I ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26125,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119170,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130873028T>G",
            "cDna": "c.1076T>G",
            "protein": "p.F359C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}